Wednesday, 20 February 2013

Lonza will generate induced pluripotent stem cells for research purposes for the US National Institutes of Health Center for Regenerative Medicine at its Walkersville, MD, facility


DSM pharma sales rise in 2012

DSM reported full year 2012 sales rising 9% to €726m, which the company attributed to increased volumes at DSM Pharmaceutical Products. DSM expects the business conditions for the pharma sector to remain challenging in 2013 but is confident of being able to deliver substantially better results during the year.

Thursday, 14 February 2013

Cambrex will manufacture hydroxypropyl methylcellulose acetate succinate for Dow Chemical for use in drug solubility enhancement


AMRI will use enzymes developed by Codexis to develop cheaper routes to manufacture APIs and intermediates

Pharmaceutical Business Review

Mixed manufacturing results at AMRI

AMRI reported development/small scale manufacturing revenues for 2012 were $35.7m, essentially flat with 2011. However, revenues for the large scale m rose 22% to $116.4m. Michael Nolan, AMRI's Vice President, Chief Financial Officer and Treasurer, said the company expects development and small scale revenues to rise up to 7% in 2013 and large scale revenue to rise up to 14%.
Seeking Alpha

Ash Stevens' expansion almost complete

Ash Stevens has completed construction on the expansion of its cGMP manufacturing facility in Riverview, MI, and expects to complete commissioning and validation by April. The new large-scale reactor bay houses 2000, 3000 and 4000L glass-lined vessels and an new isolation bay is equipped with a 1.5m2 fixed filter dryer.
Pharmaceutical Outsourcing

Tuesday, 5 February 2013

Lonza starts to restructure

Lonza will combine its custom manufacturing and bioscience business units into a pharma market segments group. The microbial control and life science ingredients businesses will be regrouped into a specialty ingredients market segments group. The company has also restructured its renamed Executive Committee. The committee will and will consist of five members: Richard Ridinger - CEO, Toralf Haag - CFO, Marc Funk - CLO, Stephan Kutzer - COO and Beat In-Albon - COO.
In-pharma Technologist

FDA leaders are considering a scorecard for quality of manufacturing facilities

Regulatory Focus

Bend Research's Oregon facility has received certification of compliance with European Union GMP regulations by Sweden’s Medical Products Agency

Bend Research

Johnson Matthey reported sales of £63m for its fine chemicals division in Q3

Johnson Matthey

Ben Venue restrained from manufacturing

Boehringer Ingelheim's Ben Venue Laboratories Bedford, Ohio, facility will no be able to manufacture and distribute drugs until the FDA determines that its operations are compliant with the Federal Food, Drug, and Cosmetic Act.
Thomson Reuters

Girindus America's Reading, OH, facility has been acquired Nitto Denko Avecia for $9.5m as part of the previously announced acquisition

Cincinnati Business Courier